Dishman Carbogen Amcis rises as its arm completes USFDA pre-approval inspection at Switzerland site | | Udaipur News | Udaipur Latest News | udaipur local news । Udaipur Updates
Home / BUSINESS / Dishman Carbogen Amcis rises as its arm completes USFDA pre-approval inspection at Switzerland site

Dishman Carbogen Amcis rises as its arm completes USFDA pre-approval inspection at Switzerland site

Dishman Carbogen Amcis is currently trading at Rs. 207.60, up by 0.55 points or 0.27% from its previous closing of Rs. 207.05 on the BSE.

The scrip opened at Rs. 209.40 and has touched a high and low of Rs. 209.60 and Rs. 206.15 respectively. So far 1045 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 314.65 on 03-Sep-2018 and a 52 week low of Rs. 180.35 on 26-Feb-2019.

Last one week high and low of the scrip stood at Rs. 218.30 and Rs. 197.00 respectively. The current market cap of the company is Rs. 3350.55 crore.

The promoters holding in the company stood at 61.40%, while Institutions and Non-Institutions held 20.99% and 17.61% respectively.

Dishman Carbogen Amcis’ wholly owned subsidiary — Carbogen Amcis AG’s manufacturing site in Neuland, Switzerland, has successfully completed a U.S. Food and Drug Administration (USFDA) pre-approval inspection. The inspection was concluded with no Form 483’s filed, thus confirming that no critical or major observation was raised during the inspection. The auditor will recommend the approval of API for which the audit was conducted.

The Hunzenschwil facility is one of Carbogen Amcis AG’s four sites to offer development and manufacturing facilities for highly potent compounds. It manufactures products according to cGMP standards and is routinely inspected by Swissmedic, the FDA and external customers.

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.

Please share this news